Reference : Cessation versus continuation of 6-month migraine preventive therapy with topiramate ...
Scientific journals : Article
Human health sciences : Neurology
http://hdl.handle.net/2268/23807
Cessation versus continuation of 6-month migraine preventive therapy with topiramate (PROMPT): a randomised, double-blind, placebo-controlled trial
English
Diener, Hans-Christoph [> > > >]
Agosti, Reto [> > > >]
Allais, Gianni [> > > >]
Bergmans, Paul [> > > >]
Bussone, Gennaro [> > > >]
Davies, Brendan [> > > >]
Ertas, Mustafa [> > > >]
Lanteri-Minet, Michel [> > > >]
Reuter, Uwe [> > > >]
Del Rio, Margarita Sanchez [> > > >]
Schoenen, Jean mailto [Université de Liège - ULiège > Département des sciences biomédicales et précliniques > Neuro-anatomie]
Schwalen, Susanne [> > > >]
van Oene, Joop [> > > >]
Dec-2007
Lancet Neurology
Lancet Ltd
6
12
1054-1062
Yes (verified by ORBi)
International
1474-4422
London
[en] Background Use of preventive therapy for migraine is often recommended for only 6-9 months, but no randomised, placebo-controlled trials have investigated migraine frequency after the end of prophylaxis. We assessed the effects of discontinuation of topiramate after a treatment period of 6 months. Methods 818 patients who have migraines were enrolled from 88 clinics in 21 countries. After a 4-8-week lead-in period, patients received topiramate in a 26-week open-label phase. Daily dose was increased from 25 mg to 100 mg in steps of 25 mg every week; the dose could be adjusted further in the range 50-200 mg/day, but was stable for the final 4 weeks. Patients were randomly assigned to continue this dose or switch to placebo for a 26-week double-blind phase. The primary endpoint was the difference in number of days with migraine during the last 4 weeks of the double-blind phase compared with the last 4 weeks of the open-label phase. Analysis was by intention to treat. This trial is registered with EudraCT, number 2005-000321-29. Findings 559 patients (68.3%) completed the open-label phase; 514 entered the double-blind phase and were assigned to topiramate (n=255) or placebo (n=259). The mean increase in number of migraine days was greater in the placebo group (1.19 days in 4 weeks, 95% CI 0.71 to 1.66; p < 0.0001) than in the topiramate group (0.10, -0.36 to 0.56; p=0.5756; mean difference between groups -1.09, -1.75 to -0.43). Patients in the placebo group had a greater number of days on acute medication than did those in the topiramate group (mean difference between groups -0.95, -1.49 to -0.41; p=0.0007). Quality of life, as assessed by the MIDAS questionnaire, fell in the placebo group but remained stable in the topiramate group. Patients were more satisfied with the efficacy of topiramate than with that of placebo, whereas satisfaction with tolerability was similar in both treatment groups. Interpretation Sustained benefit was reported after discontinuation of topiramate, although number of migraine days did increase. These findings suggest that patients should be treated for 6 months, with the option to continue to 12 months in some patients.
http://hdl.handle.net/2268/23807
10.1016/S1474-4422(07)70272-7

File(s) associated to this reference

Fulltext file(s):

FileCommentaryVersionSizeAccess
Restricted access
Cessation vs continuation Diener et al 07.pdfNo commentaryPublisher postprint184.84 kBRequest copy

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.